GERD Clinical Trial
Official title:
An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy
Sleeve gastrectomy (SG) has gained popularity as both a staged and a definitive procedure
for morbid obesity due to its technical simplicity, low-morbidity and excellent results both
for weight loss and control of metabolic syndrome. There are however reports of SG worsening
pre-existing GERD or causing new-onset GERD. Because of this, patients with pre-existing
GERD have been denied the benefits of SG. In addition, patients that develop post-op GERD
cannot undergo traditional anti-reflux surgery since the gastric fundus that is required for
fundoplication is removed during the SG. Hence, patients with post-SG GERD not adequately
controlled with medication can only opt for the more invasive gastric bypass procedure as
their only surgical treatment option.
In a recently reported case study, an obese patient with severe GERD successfully treated
with EndoStim underwent SG and maintained adequate GERD control with continued use of LES
stimulation therapy. However electrical stimulation was not yet tested systematically in
patients with prior gastric operation such as sleeve gastrectomy.
This study will test the hypothesis that electrical stimulation is effective in control of
GERD associated with SG.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | February 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Subject is between 18 - 80 years of age. 2. Subject underwent a sleeve gastrectomy minimum one year prior to enrollment (in order to have reached a stable weight loss plateau). 3. Subject has a history of heartburn, regurgitation or both for >6 month prompting physician recommendation of continual daily use of PPI after sleeve gastrectomy. 4. Baseline off-PPI GERD-HRQL score = 20 following 10-14 days off PPI 5. Baseline off-PPI GERD-HRQLscore is at least 5 points higher than the on-PPI score or a positive relationship between the occurrence of their primary symptom during the pH impedance monitoring (symptom association probability = 95% or a SI score = 50%) is present. 6. Subject who are on standard medical therapy for 6 months or longer and experience discomfort or who are otherwise dissatisfied with GERD symptoms. 7. Subjects with a GERD condition that in the opinion of the PI justifies a minimally invasive reversible procedure prior to attempting a more drastic procedure such as a gastric bypass. 8. Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry of antisecretory therapy performed within 6 months of screening visit; pH < 4 for > 6% of total time. 9. Subject has a resting LES end expiratory pressure = 5mmHg on manometry performed within 6 months of enrollment. 10. Subject has no esophagitis or esophagitis = Grade C (LA classification) on upper endoscopy within 6 months of enrollment. 11. Subject has esophageal body contraction amplitude > 30 mmHg for >30% of swallows and > 30% peristaltic contractions on manometry. 12. Subject has signed the informed consent form and is able to adhere to study visit schedule. Exclusion Criteria: 1. Subject has any non-GERD esophageal motility disorders. 2. Subject has evidence of obstruction or stricture in the gastric sleeve by a barium swallow and endoscopy. 3. Subject has any significant multisystem diseases. 4. Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma, dematomyositis, Calcinosis-Raynaud's-Esophagus Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome) requiring therapy in the preceding 2 years. 5. Subject has Barrett's epithelium (> M2; >C1) or any grade of dysplasia. 6. Subject has a hiatal hernia larger than 3 cm. 7. Subject has a body mass index (BMI) greater than 35 kg/m2. 8. Subject has Type 1 Diabetes Mellitus 9. Subject has uncontrolled Type 2 Diabetes Mellitus (T2DM) defined as HbA1c >9.5 in the previous 6 months, or has T2DM for > 10 years. 10. Subject has a history of suspected or confirmed esophageal or gastric cancer. 11. Subject has esophageal or gastric varices. 12. Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease. 13. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD). 14. Subject requires chronic anticoagulant therapy. 15. Subject has dysphagia or esophageal peptic stricture, excluding Schatzki's ring. 16. Subject of child-bearing potential who is pregnant or intends to become pregnant during the trial period. 17. Subject is currently enrolled in other potentially confounding research. 18. History of any malignancy in the last 2 years. 19. Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial. 20. Weight change of +/- 10% of the EWL (Excess Weight Loss) in the 3 months prior to enrollment. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University Medical Center | Maastricht |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | EndoStim Inc. |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence and severity of any complications that are associated with the investigational stimulation device throughout the follow-up period. | up to 12 month follow-up | Yes | |
Primary | Efficacy - Disease specific quality of life | The change in patient's GERD-HRQL, where applicable, from baseline (as measured while off PPI) . | Baseline, 6 and 12 month follow up | No |
Secondary | pH-monitoring | The change in baseline pH values of % 24-hour esophageal pH< 4.0 and number of reflux events >1minute and >5 minute duration with the same on-stimulation pH parameters at 6 months and at 12 months. | Baseline, 6 and 12 month FU | No |
Secondary | Questionnairres, symptom diary | Change in symptoms frequency and severity at 6 months vs. baseline and at 12 months vs. baseline as measured by patient symptom diary, structured GI questionnaire, and patients quality of life measured by SF-12. | baseline, 6 and 12 month FU | No |
Secondary | Anti-secretory medication use | Change in anti-secretory medication use as evaluated during the two weeks prior to the 6 mo and 12 mo follow up compared to baseline. | Baseline, 6 and 12 month FU | No |
Secondary | HR-manometry | Change in LES end expiratory pressure (LESPpre) and the on-stimulation LES end expiratory pressure (LESPpost) at 6 months and 12 months in mmHg. | Baseline, 6 and 12 month FU | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06084572 -
Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
|
||
Completed |
NCT03568825 -
Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose
|
N/A | |
Recruiting |
NCT04703374 -
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04120025 -
Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients
|
N/A | |
Withdrawn |
NCT04771247 -
Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT02575287 -
Minimal Injuries From Esophagus Detected by Optical Enhancement Systemâ„¢ Associated to Optical Magnification HD Scopes
|
N/A | |
Completed |
NCT01710800 -
Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
|
N/A | |
Completed |
NCT00287339 -
The Utility of Nexium in Chronic Cough and Reflux Disease
|
Phase 4 | |
Completed |
NCT00287391 -
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00629564 -
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT04243668 -
ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)
|
N/A | |
Completed |
NCT03558477 -
PK/PD Clinical Trial of YYD601 in Healthy Adult Male
|
Phase 1 | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Completed |
NCT05069493 -
Long-term Follow-up After Hiatal Hernia Repair by Tension-free Mesh Closure or Simple Suturing
|
||
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT03238534 -
Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
|
Phase 4 | |
Recruiting |
NCT05974722 -
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
|
N/A | |
Recruiting |
NCT05781347 -
Stretta Versus Conservative Treatment in Obese and Non-obese
|
N/A | |
Completed |
NCT06141577 -
A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05108038 -
A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects
|
Phase 1 |